12:00 AM
 | 
Mar 30, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

GLP1-PEG: Phase Ib started

Eli Lilly began a double-blind, placebo-controlled, U.S. Phase Ib trial to evaluate 14 mg of subcutaneous LY2428757 given once weekly in combination with 2 or 3 mg...

Read the full 114 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >